Incyte to stop Jakafi pancreatic, colorectal cancer drug trials
February 11, 2016Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer
Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …
ABPI appoints Mike Thompson as new chief executive
February 11, 2016Medical Communications
The Association of the British Pharmaceutical Industry (ABPI) has appointed former GlaxoSmithKline executive Mike Thompson as its new chief executive …
Genomics England enters bioinformatics partnership with Illumina
February 11, 2016Research and Development Genomics england, Illumia
Genomics England has announced a new partnership with US-based sequencing specialist Illumina to develop a platform and knowledge base that …
Alzheimer’s disease market set to double to $10.4 Billion by 2021
February 11, 2016Research and Development, Sales and Marketing Alzheimer's disease
The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion …
EMA accepts Sandoz Neulasta biosimilar for review
February 11, 2016Research and Development Amgen, Neulasta, Novartis, Sandoz
Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …
Sandoz’s Carol Lynch elected to chair European Biosimilars Group
February 10, 2016Medical Communications biosimilars
The European Generic Medicines Association (EGA) has elected Carol Lynch, global head of Biopharmaceuticals & Oncology Injectables at Sandoz, as …
MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst
February 10, 2016Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C
The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …
NICE publishes new myeloma guidance
February 10, 2016Medical Communications, Research and Development Farydak, Novartis, multiple myeloma
NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …
Novartis says CDF proposals place “unreasonable” risk on pharma
February 10, 2016Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis
Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …
Heptares announces positive early-stage dementia trial results
February 10, 2016Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia
Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …
FDA advisory committee recommends approval of Remicade biosimilar
February 10, 2016Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion
An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …
New breast cancer initiative brings together pharma and Europe’s top researchers
February 9, 2016Medical Communications, Research and Development Pfizer, breast cancer
The UK charity Breast Cancer Now (BCN) has announced a new initiative seeking to bring together Europe’s top researchers and …
Pfizer names leadership team post-Allergan merger
February 9, 2016Manufacturing and Production, Sales and Marketing Allergan, Pfizer
Pfizer has announced the executive leadership team for the combined Pfizer and Allergan business once the $160 billiion merger deal …
INTERVIEW: Tackling the Zika threat
February 9, 2016Manufacturing and Production, Medical Communications Zika, vaccines
The Zika outbreak which started in Brazil and spread rapidly to other south American countries and beyond has taken the …
FDA set to approve Remicade biosimilar
February 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Remicade, biosimilars, remsima
An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …
NICE changes mind on Amgen’s cholesterol drug
February 8, 2016Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha
NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …
Merck partners with Ugandan Health Ministry to tackle cancer awareness
February 8, 2016Manufacturing and Production, Medical Communications Africa, Cancer, Merck
Germany’s Merck celebrated World Cancer Day by collaborating with the Uganda Ministry of Health to raise awareness about early detection …
NICE rejects cholesterol drug Praluent in draft guidance
February 8, 2016Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol
NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …
UK Health Secretary sets out £4.2 billion ‘digital NHS’ vision
February 8, 2016Medical Communications, Sales and Marketing Jeremy Hunt, NHS
UK Health Secretary Jeremy Hunt has announced a £4.2 billion investment in the National Health Service (NHS) which will help …
FDA to decide on Shire blockbuster hopeful
February 8, 2016Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast
The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
